Epilepsy is a chronic disorder of the brain with substantial morbidity. There are more than 65 million people with epilepsy globally, and this is growing because of the rapidly increasing population. The rising prevalence population in Asia-Pacific (APAC) has driven revenue growth.
The morbidity and mortality associated with epilepsy are considerable. Epilepsy has the greatest impact on quality of life of all the chronic diseases, including diabetes, arthritis, and hypertension. Due to social stigma patients are reluctant to visit physicians. The poor long-term prognosis associated with epilepsy has created a pressing need for improved therapeutic options.
The marketed drug landscape contains hydantoins (phenytoin and fosphenytoin), iminostilbenes (carbamazepine and oxcarbazepine), succinimides (ethosuximide), aliphatic carboxylic acid (valproic acid) benzodiazepines (clonazepam, diazepam, lorazepam and clobazam), phenyltriazine (lamotrigine), cyclic GABA analogues (gabapentin and pregabalin), and newer drugs (levetiracetam, vigabatrin, tiagabine, lacosamide, felbamate, rufinamide, and brivaracetam). However, significant unmet need exists for disease-modifying therapies and